Kinaxis Announces Executive Leadership Changes
Kinaxis Inc.® (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced that John Sicard, president and chief executive officer (CEO) of Kinaxis, will retire from his role effective December 31, 2024 after an incredibly successful three-decade career with the company. John will retain a consultancy role with Kinaxis throughout 2025 and the Board of Directors has commenced a search for his successor.
Since Sicard’s appointment to CEO in 2016, Kinaxis has quadrupled revenue, more than tripled its valuation, grown its workforce by 400% and been a recognized leader in product innovation; in the last three years alone, the company has doubled its customer base. As Kinaxis prepares for its next wave of growth – to become a $1B revenue company and to take even more of the $16B supply chain management software market – it’s shifting its focus from building to scaling.
“John has been a tireless and inspiring leader as CEO for the past nine years, and throughout his nearly three decades of his tenure at the company,” saidRobert (Bob) Courteau, board chair. “He started his career at Kinaxis as a core architecture and software developer, and under his stewardship the company has built a market-leading platform widely recognized by analysts, customers and partners as the industry standard in truly innovative supply chain management software. John’s passion and enthusiasm for his craft are unmatched, and we’re in an enviable position today thanks to his vision.”
Courteau continued, “As we accelerate towards our ambitious goal of becoming a $1B revenue company, we agreed that now is the right time for a CEO transition and John will play an important role in that process. We wouldn’t be in this position without the foundation that he has created over the years, we are grateful for his ongoing dedication to the company, and we’re all committed to a seamless transition to support Kinaxis’ continued trajectory.”
“I am extraordinarily proud of what we have accomplished at Kinaxis, we’ve built a globally respected leader in supply chain orchestration with unlimited potential, a loyal customer base that represents the best of supply chain excellence, and an incredible global team,” said Sicard. “It’s the right time to pass the baton to the next leader who will accelerate this momentum and I’m looking forward to witnessing the inevitable successes ahead for Kinaxis.”
In addition, Chief Sales Officer Claire Rychlewski has decided to leave the company to take advantage of an opportunity that better suits her current goals. Kinaxis thanks Claire for her contributions to Kinaxis over her five-year tenure. She was instrumental in growing the company’s sales team across EMEA, APAC and North America and in preparing the global sales team for scale. She will remain with the company until November to support a seamless transition.
The company also reaffirms its fiscal 2024 guidance provided as part of its second quarter earnings news release issued on July 31, 2024.
About Kinaxis
Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them, in service of humanity. Our powerful, AI-infused supply chain orchestration platform, Maestro™, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain – from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
Cautionary Note and Forward-Looking Information
This news release contains forward-looking information within the meaning of Canadian securities legislation. Forward-looking information relates to future events or the anticipated performance of Kinaxis and reflects management’s expectations or beliefs regarding such future events. In certain cases, statements that contain forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes” or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, or “will be taken”, “occur” or “be achieved” or the negative of these words or comparable terminology. Forward-looking information in this news release includes statements with respect to Kinaxis’ revenue and market share growth plans and goals, and the reaffirmation of its fiscal 2024 guidance. By its very nature forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual performance of Kinaxis to be materially different from any anticipated performance expressed or implied by such forward-looking information.
Forward-looking information is subject to a variety of risks and uncertainties, which could cause actual events or results to differ from those reflected in the forward-looking information, including, without limitation, the risks described under the heading “Risk Factors” in the Company’s annual information form dated March 25, 2024 for its fiscal year ended December 31, 2023, under the heading “Forward-Looking Statements” in our news release dated July 31, 2024, and other risks identified in the Company’s filings with Canadian securities regulators, which filings are available on SEDAR+ at https://www.sedarplus.ca.
The risk factors referred to above are not an exhaustive list of the factors that may affect any of the Company’s forward-looking information. Forward-looking information includes statements about the future and is inherently uncertain, and the Company’s actual achievements or other future events or conditions may differ materially from those reflected in the forward-looking information due to a variety of risks, uncertainties and other factors. The Company’s statements containing forward-looking information are based on the beliefs, expectations, and opinions of management on the date the statements are made, and the Company does not assume any obligation to update such forward-looking information if circumstances or management's beliefs, expectations or opinions should change, other than as required by applicable law. For the reasons set forth above, one should not place undue reliance on forward-looking information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827724485/en/
Contacts
Media Inquiries
Belinda Thomas | Kinaxis
bthomas@kinaxis.com
+1 613 322 9305
Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com+1 613 907 7613
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Delta-Fly Pharma Inc.: Phase I/II Combo-study of DFP-10917 with Venetoclax in Patients with AML Initiates Enrollment of Patients10.9.2024 14:00:00 EEST | Press release
Following to the previous information on April 8th. 2024, we are excited to share our latest development status. A Phase I/II clinical trial of DFP-10917 in combination with Venetoclax (VEN) in patients with acute myeloid leukemia (AML) who had one prior treatment with VEN involved regimen was approved by the US Food and Drug Administration (FDA) on April 8 this year (Delta-Fly Pharma Inc.: Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 combined with Venetoclax | Business Wire). Subsequently, we are pleased to announce that the first patient was enrolled at the University of Virginia Hospital based on the approval of the Investigational Review Board (IRB). The University of Virginia Hospital is the clinical site that enrolled the most patients to the Phase III study of DFP-10917 monotherapy in patients with failed/relapsed AML. Some pharmaceutical companies have already expressed interest in the Phase III study of DFP-10917 monotherapy. Additionally, many companie
SLB achieves breakthrough results in sustainable lithium production10.9.2024 13:56:00 EEST | Press release
SLB today announced it has proven its solution for sustainable lithium production at scale at its demonstration plant in Clayton Valley, Nevada, to accelerate responsibly-sourced lithium products to market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240909767336/en/ SLB's demonstration plant in Clayton Valley proves its unique integrated approach to produce scalable quantities of lithium in the fastest, most economical and sustainable way for today’s market. (Photo: Business Wire) The proprietary integrated solution combines SLB’s subsurface expertise with surface engineering of advanced technologies that include direct lithium extraction (DLE). It produces lithium 500 times faster than conventional methods while using only 10 percent of the land. Operating at approximately one tenth the size of a commercial-scale facility, the plant reached a verified recovery rate1 of 96% lithium from brine. SLB’s integrated solution i
Eaton to Showcase Technologies for Hydrogen-Powered Commercial Vehicles at IAA Transportation 202410.9.2024 13:30:00 EEST | Press release
Intelligent power management company Eaton announced it will showcase a broad range of innovative solutions for hydrogen-powered commercial vehicles September 17–22 at IAA Transportation 2024 in Hanover, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910157651/en/ Eaton’s hydrogen recirculation blower cycles surplus hydrogen to the stack's inlet, which extends system longevity through anode purging. (Photo: Business Wire) “Eaton believes that hydrogen can play a significant role in decarbonizing commercial vehicles,” said Scott Adams, senior vice president, Global Products, Eaton’s Mobility Group. “Whether a vehicle is powered by hydrogen fuel cells or a hydrogen internal combustion engine, Eaton’s broad range of innovative solutions makes us a valuable supplier partner.” Eaton’s TVS technology improves fuel cell performance Recirculating excess hydrogen through the fuel cell stack is critical for achieving high
The LYCRA Company Presents Seminars on Sustainable Elastane Solutions at the 63rd Dornbirn Global Fiber Congress10.9.2024 12:00:00 EEST | Press release
The LYCRA Company, a global leader in developing innovative and sustainable fiber and technology solutions for the apparel and personal care industries, announced today that company representatives will give presentations at the Dornbirn Global Fiber Congress (GFC), September 11 - 13 in Dornbirn, Austria. These presentations cover two key initiatives within the roadmap and vision of The LYCRA Company’s Planet Agenda platform and 2030 Sustainability Goals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910079150/en/ The LYCRA Company Presents Seminars on Sustainable Elastane Solutions at the 63rd Dornbirn Global Fiber Congress (Photo: Business Wire) Jean Hegedus, The LYCRA Company’s director of sustainable business development, will present “From Farm to Fiber: Developing Elastane with 70% Bio-Derived Content” on September 11 at 14:20 CEST (Kulturhaus Room B). She will be joined by Andrea Vanderhoff, director of technology
CorFlow Therapeutics AG Completes €44 Million Series B Financing to Support the Advancement of a Novel Diagnostic and Drug Delivery Platform for Microvascular Obstruction (MVO) in Heart Attack Patients10.9.2024 11:00:00 EEST | Press release
CorFlow Therapeutics AG (CorFlow) announced today that it has raised €44 million in Series B funding, co-led by Broadview Ventures and Panakes Partners with strong continued support from 415 Capital, CorFlow's initial VC investor and largest shareholder. Merieux Equity Partners, Laerdal Million Lives Fund, Wellington Partners, M&L Investments, Unorthodox Ventures, KOFA Healthcare and Monte Carlo Capital participated in the multinational syndicate. Concurrent with the financing, David Prim of Broadview Ventures, Barbara Castellano of Panakes Partners, Yoann Bonnamour of Merieux Equity Partners, and Rhiya Pau of Laerdal Million Lives Fund have joined the CorFlow Board of Directors. The Series B will fund the MOCA II (MVO with CoFITM System Assessment II) pivotal study intended to gain US market clearance. The trial will run in the US and Europe and aims to validate CorFlow’s CoFl system to diagnose MVO in heart attack patients immediately following stent implantation. Additionally, it wi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom